Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron or phenazopyridine during intravesical BCG for non-muscle invasive bladder cancer
ACTRN12625001397404Phase 3Not yet recruiting
- Sponsor
- Southern Adelaide Local Health Network
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in non-muscle-invasive bladder cancer (NMIBC) comparing Mirabegron + BCG, Phenazopyridine hydrochloride + BCG and Placebo + BCG (3 arms). Primary endpoints: Quality of life in patients undergoing BCG intravesical therapy for non-muscle invasive bladder cancer and Bladder pain and symptom burden. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
mirabegronphenazopyridine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ACTRN12625001397404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001397404.